Abstract：
UNASSIGNED: This systematic review and meta-analysis focussed on insights into the relationship between CACNA1C-rs1006737 and ZNF804A-rs1344706 polymorphisms and cognitive performance in schizophrenia (SCZ) spectrum and bipolar disorder (BD) and provide some contributions for clinical practice.
UNASSIGNED: We searched the websites databases (PubMED, PsycINFO, Web of Science, EMBASE and Cochrane Library) using eligibility and exclusion criteria to capture all potential studies, based on PICO model and according to the PRISMA.
UNASSIGNED: Eight articles were included in this systematic review (five referring to CACNA1C-rs1006737 and three related to ZNF804A-rs1344706 polymorphisms), with a total of 5759 participants (1751 SCZ patients, 348 BD patients, 3626 controls and 34 first-degree relatives). The results demonstrated that the pooled effect of CACNA1C-rs1006737 (risk difference RD = 0.08; 95% CI 0.02-0.15) was associated with altered cognitive function in patients with severe mental disorders, but not ZNF804A-rs1344706 polymorphism (RD = 0.19; 95% CI 0.09-0.48.
UNASSIGNED: The present meta-analysis provides evidence regarding slight association between CACNA1C-rs1006737 polymorphisms and cognitive performance in severe mental disorders, indicating that cognitive impairment in severe mental disorders associated with the CACNA1C rs1006737 risk variants could only be expressed when interacting with environmental exposures. This study is registered with PROSPERO, number CRD42021246726.
UNASSIGNED: We searched the websites databases (PubMED, PsycINFO, Web of Science, EMBASE and Cochrane Library) using eligibility and exclusion criteria to capture all potential studies, based on PICO model and according to the PRISMA.
UNASSIGNED: Eight articles were included in this systematic review (five referring to CACNA1C-rs1006737 and three related to ZNF804A-rs1344706 polymorphisms), with a total of 5759 participants (1751 SCZ patients, 348 BD patients, 3626 controls and 34 first-degree relatives). The results demonstrated that the pooled effect of CACNA1C-rs1006737 (risk difference RD = 0.08; 95% CI 0.02-0.15) was associated with altered cognitive function in patients with severe mental disorders, but not ZNF804A-rs1344706 polymorphism (RD = 0.19; 95% CI 0.09-0.48.
UNASSIGNED: The present meta-analysis provides evidence regarding slight association between CACNA1C-rs1006737 polymorphisms and cognitive performance in severe mental disorders, indicating that cognitive impairment in severe mental disorders associated with the CACNA1C rs1006737 risk variants could only be expressed when interacting with environmental exposures. This study is registered with PROSPERO, number CRD42021246726.
摘要：
UNASSIGNED：本系统综述和荟萃分析集中于对CACNA1C-rs1006737和ZNF804A-rs1344706多态性与精神分裂症（SCZ）谱和双相情感障碍（BD）认知表现之间关系的见解，并为临床实践提供了一些贡献。
UNASSIGNED：我们搜索了网站数据库（PubMED，PsycINFO,WebofScience,EMBASE和Cochrane图书馆）使用资格和排除标准来捕获所有潜在的研究，基于PICO模型和PRISMA。
UNASSIGNED：本系统综述包括8篇文章（5篇涉及CACNA1C-rs1006737，3篇涉及ZNF804A-rs1344706多态性），共有5759名参与者(1751名SCZ患者，348例BD患者，3626个对照和34个一级亲属)。结果表明，CACNA1C-rs1006737的合并效应（风险差异RD=0.08;95％CI0.02-0.15）与严重精神障碍患者的认知功能改变有关，但不是ZNF804A-rs1344706多态性(RD=0.19；95%CI0.09-0.48。
UASSIGNED：本荟萃分析提供了关于严重精神障碍中CACNA1C-rs1006737多态性与认知表现之间轻微关联的证据，这表明与CACNA1Crs1006737风险变异相关的严重精神障碍中的认知障碍只能在与环境暴露相互作用时表达。这项研究在PROSPERO注册，编号CRD42021246726。
UNASSIGNED：我们搜索了网站数据库（PubMED，PsycINFO,WebofScience,EMBASE和Cochrane图书馆）使用资格和排除标准来捕获所有潜在的研究，基于PICO模型和PRISMA。
UNASSIGNED：本系统综述包括8篇文章（5篇涉及CACNA1C-rs1006737，3篇涉及ZNF804A-rs1344706多态性），共有5759名参与者(1751名SCZ患者，348例BD患者，3626个对照和34个一级亲属)。结果表明，CACNA1C-rs1006737的合并效应（风险差异RD=0.08;95％CI0.02-0.15）与严重精神障碍患者的认知功能改变有关，但不是ZNF804A-rs1344706多态性(RD=0.19；95%CI0.09-0.48。
UASSIGNED：本荟萃分析提供了关于严重精神障碍中CACNA1C-rs1006737多态性与认知表现之间轻微关联的证据，这表明与CACNA1Crs1006737风险变异相关的严重精神障碍中的认知障碍只能在与环境暴露相互作用时表达。这项研究在PROSPERO注册，编号CRD42021246726。
